United Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
United Therapeutics heeft een totaal eigen vermogen van $6.1B en een totale schuld van $400.0M, wat de schuld-eigenvermogensverhouding op 6.6% brengt. De totale activa en totale passiva bedragen respectievelijk $7.1B en $1.0B. De EBIT United Therapeutics is $1.3B waardoor de rentedekking -8.9 is. Het heeft contanten en kortetermijnbeleggingen van $3.3B.
Belangrijke informatie
6.6%
Verhouding schuld/eigen vermogen
US$400.00m
Schuld
Rente dekkingsratio | -8.9x |
Contant | US$3.33b |
Aandelen | US$6.10b |
Totaal verplichtingen | US$1.02b |
Totaal activa | US$7.12b |
Recente financiële gezondheidsupdates
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $4.0B ) UTHR } overtreffen de korte termijn passiva ( $873.4M ).
Langlopende schulden: De kortetermijnactiva UTHR ( $4.0B ) overtreffen de langetermijnschulden ( $148.8M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: UTHR heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van UTHR is de afgelopen 5 jaar gedaald van 36.8% naar 6.6%.
Schuldendekking: De schuld van UTHR wordt goed gedekt door de operationele kasstroom ( 284.2% ).
Rentedekking: UTHR verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.